A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins - Enoxaparin, nadroparin and dalteparin: The ESCAPe-END study

Pharmacology

Volumn 78, Issue 3, 2006, Pages 136-143

  Shafiq, N ^a   Malhotra, S ^a   Pandhi, P ^a   Sharma, N ^a   Bhalla, A ^a   Grover, A ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Low molecular weight heparin; Low molecular weight heparin, cost effectiveness; Low molecular weight heparins, a comparison; PAI 1 levels, randomized trial

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; ANGINA PECTORIS; ARTICLE; BLEEDING; CALCULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SILENT MYOCARDIAL ISCHEMIA; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADULT; AGED; ANGINA, UNSTABLE; COST-BENEFIT ANALYSIS; DALTEPARIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NADROPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES;

EID: 33751114649     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096484     Document Type: Article

References (22)

1. Majerus PW, Tollesfsen DM: Anticoagulant, thrombolytic and antiplatelet drugs; in Hardman JG, Limbird LE, Gilman AG (eds): Goodman and Gilman's Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 2001, pp 1519-1538.
2. Weitz JI: Low molecular weight heparins. N Engl J Med 1997;337:688-698.
3. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group: Low molecular weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
4. Fragmin and Fast Revascularization during Instability in Coronary Artery Disease (FRISC II) Investigators: Long-term low molecular weight heparin in unstable coronary artery disease. FRISC II prospective randomized multicentre study. Lancet 1999;354:701-704.
5. FRAX IS Study Group: Comparison of two treatment durations (6 and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. Eur Heart J 1990;20:1553-1562.
6. Gurfinkel EP, Mejail RI: Low molecular weight heparin versus regular heparin and aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995:26:313-318.
7. Klein W, Buchwald A, Hillis WS, Monrad S, Sanz G, Turpie AG, Vander Meer J, Olaisson E, Undeland S, Ludwig K: Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61-68.
8. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F: Low-molecular-weight heparins in non-STsegment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events. Am J Cardiol 1998;82:19L-24L.
9. Malhotra S, Bhargava VK, Grover A, Pandhi P, Sharma YP: A randomized trial to compare the efficacy, safety, cost and platelet aggregation effects of enoxaparin and unfractionated heparin (the ESCAPEU trial). Int J Clin Pharmacol Ther 2001;39:110-115.
10. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
11. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM: Low molecular weight heparin: pharmacological profile and product differentiation. Am J Cardiol 1998;14(suppl):28E-34E.
12. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM: Low molecular weight heparin: pharmacological profile and product differentiation. Am J Cardiol 1998;82(suppl 3B):3L-10L.
13. Michalis LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J, Sideris DA: Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003;146:304-310.
14. Okmen E, Ozen E, Uyarel H, Sanli A, Tartan Z, Cam N: Effects of enoxaparin and nadroparin on major cardiac events in highrisk unstable angina treated with a glycoprotein IIB/IIIa inhibitor. Jpn Heart J 2003;44:899-906.
15. Tsikouris JP, Suarez JA, Meyerrose GE: Plasminogen activator inhibitor-1: physiological role, regulation, and the influence of common pharmacological agents. J Clin Pharmacol 2002;42:1187-1199.
16. Braunwald E: Unstable angina: a classification. Circulation 1989;80:410-414.
17. Antman EM, Cohen M, Radley D, et al: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
18. Perez-Ruiz A, Montes R, Carrasio P, Rocha E: Effect of a low molecular weight heparin, on hemostatic properties of endothelium. Clin Appl Thromb Hemost 2002;8;65-71.
19. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction Lancet 1987;ii:3-9.
20. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-2247.
21. Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AG, Califf RM, Weatherley B, Cohen M: Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998;97:1702-1707.
22. Davey PG, Malek M, Dodd T, MacDonald T: Pharmacoeconomics and drug prescribing; in Speight TM, Holford HG (eds): Avery's Drug Treatment, ed 4. New York, McGraw-Hill, 1997, pp 393-422.